RhoGDI2 as a therapeutic target in cancer
Authors:
- 9 December 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 14 (1) , 67-75
Abstract
(2010). RhoGDI2 as a therapeutic target in cancer. Expert Opinion on Therapeutic Targets: Vol. 14, No. 1, pp. 67-75. doi: 10.1517/14728220903449251Keywords
This publication has 73 references indexed in Scilit:
- ZAK negatively regulates RhoGDIβ-induced Rac1-mediated hypertrophic growth and cell migrationJournal of Biomedical Science, 2009
- Silencing of D4-GDI Inhibits Growth and Invasive Behavior in MDA-MB-231 Cells by Activation of Rac-dependent p38 and JNK SignalingJournal of Biological Chemistry, 2009
- Src phosphorylation of RhoGDI2 regulates its metastasis suppressor functionProceedings of the National Academy of Sciences, 2009
- Rho GDP Dissociation Inhibitor 2 Suppresses Metastasis via Unconventional Regulation of RhoGTPasesCancer Research, 2009
- Diacylglycerol Kinase ζ Regulates Actin Cytoskeleton Reorganization through Dissociation of Rac1 from RhoGDIMolecular Biology of the Cell, 2009
- RhoGDIβ-induced hypertrophic growth in H9c2 cells is negatively regulated by ZAKJournal of Biomedical Science, 2009
- Rho GTPases in cancer cell biologyFEBS Letters, 2008
- Metastasis: a therapeutic target for cancerNature Clinical Practice Oncology, 2008
- Phosphorylation of RhoGDI by Src Regulates Rho GTPase Binding and Cytosol-Membrane CyclingMolecular Biology of the Cell, 2006
- The Guanine Nucleotide-Binding Switch in Three DimensionsScience, 2001